Lundbeck and IBM collaborating on use of artificial intelligence for research purposes

The pharmaceutical company H. Lundbeck A/S has established a new and innovative collaboration with IBM on access to the IBM Watson super computer. Plesner advised Lundbeck on the agreement.

In the years to come, knowledge from Lundbeck's brain research is to be combined with IBM's cognitive Watson super computer. IBM Watson is to be used to strengthen Lundbeck's development of drugs for the treatment of schizophrenia, Parkinson's disease and other neurological disorders.

The collaboration means that Lundbeck will get access to anonymous health data from millions of patients in the Watson Health Cloud.

Because of Watson, IBM is a world leader in the development of artificial intelligence. Read more on IBM's website. The partnership with Lundbeck means that the IBM Watson computer's ability to process data is further improved.

Latest news on Technology, Media and Telecoms (TMT) Law

Technology, Media and Telecoms (TMT) Law